NCT03175198 - Japanese Pradaxa PMS, Long Term | Biotech Hunter

Enrollment

5,660

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

December 21, 2020

Study Completion Date

January 12, 2021

Conditions

Atrial Fibrillation

Interventions

DRUG

Prazaxa® Capsules

Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg \[as 2 capsules of 75 mg\] twice a day (b.i.d)) or 220 mg (110 mg \[as 1 capsule of 110 mg\] b.i.d) for a treatment duration of 52 weeks.

Trial Locations (1)

Unknown

Nippon Boehringer Ingelheim Co., Ltd, Tokyo